

# PAD VOLUME I

## Index of Tables and Figures

PAD Consequences	2
Consequences of Critical Limb Ischemia and First Stroke.	3
Percentage of Patients With Intermittent Claudication.	3
Cause of Death in PAD.	4
Five-Year All Cause Mortality for Selected Diseases	5
Ten-Year Mortality for PAD by Disease Severity Compared With Survivors of First Heart Attack	5
Percentage of PAD Patients With CAD or CVD	6
Five-Year Mortality and Incidence of Non-Fatal MI or Stroke	6
Six-Year Cardiovascular Morbidity Increases With Severity of PAD	7
Six-Year Mortality Increases With Severity of PAD	7
Major Risk Factors for PAD	8
Five-Year All-Cause Mortality for PAD with Smoking or CAD Compared to Controls	9
Guidelines for Total Cholesterol	10
Guidelines for LDL Cholesterol	11
Multiple Risk Factors Increase the Risk of PAD	12
Ankle Brachial Index (ABI)	13
ABI and PAD— Severity and Symptoms	14
Estimated Number of People with PAD 2000	16
Percentage of the U.S. Population with Diagnosed Diabetes	16
Percentage of Diabetics and Non-Diabetics with PAD	17
Estimated Number of People with PAD 2000-2020	18
PAD Prevalence Compared to Other Serious Diseases	18
The MCVI Survey of Primary Care Physicians (PCPs)	19
PAD and Diabetes Estimated Percentage of Patients Diagnosed	20
Legs For Life® Screening Results	21
Treatment of PAD	21
Risk Factor Modification	21
Standard Drug Therapy	23
Pharmaceutical Therapy for Hypertension	26
ACE Inhibitors	28
Angiotensin Receptor Blockers (Antagonists)	29
Antiplatelets	30
Lipid-Lowering Agents Statins and Cholesterol Absorbtion Inhibitors	33

Other Lipid-Lowering Agents	37
Cholesterol Reduction And Vascular Remodeling In The Lower Limbs	39
Guidelines for HDL Cholesterol	40
Characteristics of Common Dyslipidemia Patterns In CAD, PAD and Atherogenic/ Diabetic Dyslipidemia	41
Triglyceride Levels	41
New Risk Factors	42
CRP Levels and Heart Attack Risk	44
Drug Therapy for Claudication Symptoms	46
Percentage of PAD Patients Needing Treatment	47
PAD Patients Undertreated in Primary Care Setting	48
PAD Patients Undertreated Before and After Revascularization At Academic Medical Centers	48
U.S. PAD Market Potential for Drug Therapy By Therapeutic Category 2000	49
U.S. PAD Market Potential For Selected Drug Categories As The Population Ages 2000-2020	50
Estimated U.S. Market for Claudication Therapy 2000-2020	50
Estimated U.S. Sales of Claudication Drugs And Additional Market Potential 2002	51
Estimated U.S. PAD Market for Antihypertensive Therapy 2000-2020	52
U.S. Revenues of Selected ACE Inhibitors 2002	52
U.S. Revenues of Selected ARBs 2002	53
Estimated U.S. ACE and ARB Markets and Additional Market Potential With Treatment of PAD Patients 2002	53
Estimated U.S. PAD Market for Antilipids 2000-2020	54
U.S. Revenues of Selected Statins 2002	55
Estimated U.S. Lipid Reduction Market and Additional Market Potential With Treatment of PAD Patients 2002	55
Estimated U.S. PAD Market for Antiplatelet Therapy 2000-2020	56
Estimated U.S. Plavix Sales and Additional Market Potential With Treatment of PAD Patients 2002	56
Valuation Tables	57
Company Financials	59-82